Mental Disorders
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
Subtype terms (18)
More specific conditions that are subtypes of Mental Disorders in the MeSH hierarchy.
- Anxiety Disorders
244 drugs (133 approved, 111 experimental)
- Disruptive, Impulse Control, and Conduct Disorders
19 drugs (15 approved, 4 experimental)
- Dissociative Disorders
9 drugs (8 approved, 1 experimental)
- Elimination Disorders
- Feeding and Eating Disorders
64 drugs (44 approved, 20 experimental)
- Mood Disorders
88 drugs (58 approved, 30 experimental)
- Motor Disorders
2 drugs (1 approved, 1 experimental)
- Neurocognitive Disorders
30 drugs (24 approved, 6 experimental)
- Neurodevelopmental Disorders
33 drugs (21 approved, 12 experimental)
- Neurotic Disorders
3 drugs approved
- Paraphilic Disorders
- Personality Disorders
4 drugs approved
- Schizophrenia Spectrum and Other Psychotic Disorders
27 drugs (18 approved, 9 experimental)
- Sexual Dysfunctions, Psychological
18 drugs (12 approved, 6 experimental)
- Sleep Wake Disorders
99 drugs (72 approved, 27 experimental)
- Somatoform Disorders
9 drugs (6 approved, 3 experimental)
- Substance-Related Disorders
171 drugs (133 approved, 38 experimental)
- Trauma and Stressor Related Disorders
3 drugs (1 approved, 2 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (23)
Phase 3 trials (15)
Phase 2 trials (23)
Phase 1 trials (12)
Other trials (34)
- nitrous oxide
- 13c10-retinyl-acetate
- florbetaben F-18
- efavirenz
- albendazole
- buspirone
- methylphenidate
- ibuprofen
- valproic acid
- egg
- sevoflurane
- lactulose
- bovine colostrum
- amoxicillin
- iron sucrose
- lithium
- lysozyme
- ropivacaine
- prucalopride succinate
- lactoferrin
- platelets
- clonidine
- thiamine
- umbilical cord mesenchymal stem cells
- zinc dichloride
- sulfadoxine
- amisulpride
- amino acids
- midazolam
- cloxacillin
- +4 more
Organizations
Organization Involved with Phase 4 Indications (129)
- Acadia Pharmaceuticals
- Jazz Pharmaceuticals
- Cephalon
- AstraZeneca
- Eli Lilly
- Pfizer
- Sanofi-Synthelabo
- Novartis
- GlaxoSmithKline
- Otsuka
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- Douglas Sears
- National Jewish Health
- Huazhong University of Science and Technology
- Aarhus University
- Abarbanel Mental Health Center
- University of Pittsburgh
- Central South University
- AGUNCO Obstetrics and Gynecology Centre
- Augusta University
- Centro de Investigación Biomédica en Red (CIBER)
- Chulalongkorn University
- Cornell University
- Harvard University
- Dartmouth University
- University of Washington
- +99 more
Organization Involved with Phase 3 Indications (54)
- Bristol-Myers Squibb
- Merck
- Bukwang Pharmaceutical
- Corcept Therapeutics
- Solvay
- Yuyu Pharma, Inc.
- National Institute of Mental Health and Neuro Sciences, India
- UMC Utrecht
- Alexandria University
- Case Western Reserve University
- Cancer Research Network
- Clinic for Psychiatric Disorders
- Diakonhjemmet Hospital
- Duke University
- Inje University
- Norwegian University of Science and Technology
- North District Hospital
- Saint-Joseph University
- University of Oslo
- University of Southern California
- University of California, San Diego
- Zhejiang University
- Clinic for Psychiatric Disorders, Dr Laza Lazarevic
- University of Amsterdam
- Orygen Youth Research Centre
- Rush University
- The University of Hong Kong
- ZNA Antwerpen
- Hallym University
- Huddinge Hospital, Stockholm
- +24 more
Organization Involved with Phase 2 Indications (57)
- Bausch Health Companies
- Forest Laboratories
- Genentech
- Kuhnil Pharmaceutical Co., Ltd.
- Marinus Pharmaceuticals
- Mediti Pharma Inc.
- Sunovion
- Boehringer Ingelheim
- Fundación Pública Andaluza
- Research Foundation for Mental Hygiene, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cedars-Sinai Medical Center
- Chiba University
- University of London
- Herzog Hospital
- New York University
- Newcastle University
- Niuvanniemi Hospital
- Northwestern University
- Russian Academy of Medical Sciences
- Sheppard Pratt Health System
- University of Groningen
- University of Lausanne
- University of Manchester
- University of Nebraska
- University of Padova
- Soochow University
- University of Cambridge
- Uppsala University
- Vanderbilt University
- +27 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (27)
- Cumberland Pharmaceuticals
- Medical University of Graz
- Brown University
- Kyung Hee University
- Norton Healthcare
- Oregon Health and Science University
- St. Luke's-Roosevelt Hospital Center
- Tufts University
- University of Louisville
- University of Bath
- Virginia Commonwealth University
- University of Zurich
- University of Basel
- University of Minnesota
- Medical University of Vienna
- Hennepin Healthcare
- Kwai Chung Hospital
- University of Quebec
- Zucker Hillside Hospital
- LIJMC
- South London and Maudsley NHS Foundation Trust
- Canadian Institutes of Health Research (CIHR)
- McPin Foundation
- Robert Wood Johnson Foundation
- Government of Hong Kong
- Canadian Psychiatric Research Foundation
- Clinica Luganese Moncucco